Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. (28th April 2018)

• Record Type: Journal Article
• Authors: Islam, Muhammad Torequl; Ali, Eunüs S.; Uddin, Shaikh Jamal; Islam, Md. Amirul; Shaw, Subrata; Khan, Ishaq N.; Saravi, Seyed Soheil Saeedi; Ahmad, Saheem; Rehman, Shahnawaz; Gupta, Vijai Kumar; Găman, Mihnea-Alexandru; Găman, Amelia Maria; Yele, Santosh; Das, Asish Kumar; de Castro e Sousa, João Marcelo; de Moura Dantas, Sandra Maria Mendes; Rolim, Hercília Maria Lins; de Carvalho Melo-Cavalcante, Ana Amélia; Mubarak, Mohammad S.; Yarla, Nagendra Sastry; Shilpi, Jamil A.; Mishra, Siddhartha Kumar; Atanasov, Atanas G.; Kamal, Mohammad Amjad
• Is Part Of: Cancer letters. Volume 420(2018)
• Page Start: 129
• Page End: 145
• Publication Date: 2018-04-28
• Subjects: Andrographolide -- Andrographis paniculata -- Diterpene lactone -- Anticancer -- Chemotherapy -- Bioactive lactone; ACS American Chemical Society -- AKT activated protein kinase -- Andro Andrographolide derivative or conjugate -- AP-1 activator protein-1 -- Cdk Cyclin-dependent kinase -- CFSE carboxyfluorescein succinimidyl ester -- CHOP C/EBP homologous protein -- CIP1 cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) -- COX-2 cyclooxygenase-2 -- CRPC castration-resistant prostate cancer -- DLBCL diffuse large B-cell lymphoma -- ER endoplasmic reticulum -- ERK extracellular signal-regulated kinase -- FL follicular lymphoma -- GCLM glutamate cysteine ligase modifier -- GIT gastrointestinal tract -- GM-CSF granulocyte monocyte-colony stimulating factor -- GPx1 glutathione peroxidase 1 -- GRP78 glucose-regulated protein 78 -- GSH reduced glutathione -- GSSG glutathione disulfide -- H2O2 hydrogen peroxide -- HIF-1 hypoxia inducible factor 1 -- HUVECs human umbilical vein endothelial cells -- ICAM-1 intercellular adhesion molecule 1 -- IFN-γ interferon-gamma -- IgE immunoglobulin -- IL interleukin -- iNOS inducible nitric oxide synthase -- KIM-1 kidney injury molecule-1 -- LPS lipopolysaccharide -- MAPK mitogen activated protein kinase -- MCL mantle cell lymphoma -- MDA malondialdehyde -- MMP matrix metallo-protein -- MPO myeloperoxidase -- mRNA messenger RNA -- NADPH nicotinamide adenine dinucleotide phosphate -- NF-κB nuclear factor-kappa B -- NIH National Institutes of Health -- NK natural killer -- NSCLC non-small cell lung cancer -- OVA ovalbumin -- PAI-1 plasminogen activator inhibitor-1 -- PARP Poly (ADP-ribose) polymerase -- PC12 pheochromocytoma 12 -- PI3K phosphatidylinositol-4, 5-bisphosphate 3-kinase -- RA-FLSs RA fibroblast-like synoviocytes -- RAFLSs rheumatoid arthritis fibroblast-like synoviocytes -- RANKL receptor activator of nuclear factor kappa-B ligand -- ROS reactive oxygen species -- SOD superoxide dismutase -- STAT-3 signal transducer and activator of transcription 3 -- TBARS thioberbituric acid substance -- TGF-β1 tumor growth factor beta 1 -- TIMP-1 tissue inhibitor of metalloproteinases 1 -- TLR4 toll-like receptor 4 -- TNF-α tumor necrosis factor-alpha -- TRAIL TNF-related apoptosis-inducing ligand -- VEGF vascular endothelial growth factor -- X-IAP X-linked inhibitor of apoptosis protein; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2018.01.074
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: The diterpene lactone andrographolide, isolated from Andrographis paniculata, has been proven to possess several important protective biological activities, including antioxidant, anti-inflammatory, immunomodulatory, antiseptic, antimicrobial, cytotoxic, hypolipidemic, cardioprotective, hepatoprotective, and neuroprotective effects. In addition, it has been reported to play a therapeutic role in the treatment of major human diseases, such as Parkinson's disease, rheumatoid arthritis, and colitis. This systematic review aims to highlight andrographolide as a promising agent in cancer treatment. To this purpose, a number of databases were used to search for the cytotoxic/anticancer effects of andrographolide in pre-clinical and clinical studies. Among 1703 identified literature articles, 139 were included in this review; 109 were investigated as non-clinical, whereas 24, 3, and 3 were pre-clinical, clinical, and non-pre-clinical trials, respectively. Among the model systems, cultured cell lines appeared as the most frequently (79.14%) used, followed by in vivo models using rodents, among others. Furthermore, andrographolide was found to exert cytotoxic/anticancer effects on almost all types of cell lines with the underlying mechanisms involving oxidative stress, cell cycle arrest, anti-inflammatory and immune system mediated effects, apoptosis, necrosis, autophagy, inhibition of cell adhesion, proliferation, migration, invasion, anti-angiogenic activity, and other miscellaneous actions. After careful consideration of the relevant evidence, we suggest that andrographolide can be one of the potential agents in the treatment of cancer in the near future. Highlights: Andrographolide (diterpene lactone andrographolide, from Andrographis paniculata ) as a promising agent in cancer treatment. A number of databases were searched for pre-clinical and clinical trials on the anticancer effects of andrographolide. Among model systems, cultured cell lines appeared most frequently used followed by in vivo models using rodents. The various mechanisms by which this compound exerts its action are summarised. It is important to carry out toxicological studies prior to installing andrographolide into full-length clinical trials.